A carregar...
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
Objectives To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom. Design Quantitative benefit-harm and economic a...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group Ltd.
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3204867/ https://ncbi.nlm.nih.gov/pubmed/22042753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.d6333 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|